-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 8, 2022, China Biopharmaceutical Co.
According to the official website of the Center for Drug Evaluation of the State Drug Administration, TDI01 is an oral small molecule drug with a new target and a new mechanism.
Sino Biopharmaceutical is the first company in China to focus on ROCK2 targets
It is expected to help 900,000 pneumoconiosis patients
It is expected to help 900,000 pneumoconiosis patientsBy the end of 2019, about 900,000 cases of pneumoconiosis had been reported nationwide, accounting for 90% of the total number of occupational diseases.
Xie Qirun, chairman of the board of directors of Sino Biopharmaceuticals, said that as a pharmaceutical company, it has an important mission and responsibility to pay attention to the pneumoconiosis patients.